Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
Arcellx, Inc. (ACLX)
Company Research
Source: Business Wire
-- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma ---- A simulation model of CAR T use ahead of bispecific antibodies in 4L+ RRMM is estimated to reduce the risk of progression or death by 64% and death by 48% over five years versus the reverse sequence, supporting CAR T before bispecific antibody as the sequence that delivers superior improved long-term outcomes in 4L+ RRMM ---- Geographic inequities persist in CAR T access for MM patients marked by long travel, out-of-state care, and bypassed ATCs, highlighting systemic referral gaps and the need for ATC expansion to improve equitable access -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, is advancing both its scientific foundation for its D-Domain platform technology and
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]Yahoo! Finance
- Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.MarketBeat
- Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 1/20/26 - Form 4
- 1/20/26 - Form 144
- 1/14/26 - Form 144
- ACLX's page on the SEC website